# MagnetisMM-3

Source: https://onco.cc/trials/magnetismm-3/  
OnCo record `magnetismm-3` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MagnetisMM-3 is the pivotal study behind elranatamab's approval.

## Summary

MagnetisMM-3, trial NCT04649359 sponsored by Pfizer and reported in 2023, is the pivotal single-arm study behind elranatamab's approval in relapsed or refractory myeloma after at least three prior lines in BCMA-naive patients. In 123 patients the response rate was 61 percent with complete response or better in 35 percent, progression-free survival was durable, and switching to every-two-week dosing after six months maintained responses. OnCo links it to multiple myeloma, elranatamab and the MagnetisMM-3 paper. Whether reduced dosing frequency lowers infection risk without losing efficacy is the open question its design raised.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT04649359
- Phase: 2
- Setting: Relapsed/refractory myeloma after ≥3 lines, BCMA-naive: elranatamab monotherapy
- Sponsor: Pfizer
- Enrolled: 123
- Result: ORR 61%.
- Outcomes: Objective response rate: Elranatamab 61%

## Sources

- ClinicalTrials.gov NCT04649359: https://clinicaltrials.gov/study/NCT04649359

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Elranatamab](https://onco.cc/drugs/elranatamab/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- key papers: [MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response](https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/)

---
JSON: https://onco.cc/api/v1/entities/magnetismm-3.json